Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Plaque Burden on CCTA Predicts MACE in Early CAD
Added: 2 months ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ESC 25: The CARUSO Trial
Author(s): Tiziana Claudia Aranzulla Added: 8 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more

Intervention

Prevention & Chronic Conditions
Valentin Fuster
Research Area(s) / Expertise: Job title: Director and Physician-in-Chief
Dr Fuster completed his medical degree at Barcelona University in 1967 and then pursued an internship at Hospital Clínic de Barcelona. In 1971, he attended the University of Edinburgh as a research fellow in cardiovascular disease for three years under the tutelage of Desmond Julian and Harold Sheehan. He earned his PhD degree at Edinburgh University with his thesis focussing on platelet factor 4… View more
A Preferred Substrate-based Nomenclature in Myocardial Ischaemic Syndromes
Author(s): William E Boden , Juan Carlos Kaski , C Noel Bairey Merz , et al Added: 1 year ago

MI/ACS
Lp(a) and Atherosclerosis
Author(s): Annalisa Filtz , Leandro Slipczuk , Martha Gulati Added: 2 months ago

Prevention & Chronic Conditions
Confirm 2
Author(s): Alexander van Rosendael Added: 8 months ago
In this short interview, recorded at ESC 2025 (Madrid, ES) Dr Alexander R van Rosendael (Leiden University Medical Center, Leiden, NL) discusses data from the CONFIRM 2 registry, a large-scale study of clinically indicated coronary CT angiography incorporating automated, AI-guided quantification of atherosclerotic plaque. Building on prior visual-assessment registries, CONFIRM 2 applies whole… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
AI in Quantitative CT Assessments: CONFIRM2 with Dr Alexander Van Rosendael
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more

Digital Health

Intervention
New Horizons in Dyslipidaemia 2026
NHD 2026

Video Series

Author(s): Kausik Ray , Erik Stroes , Nicholas Marston , et al Added: 2 months ago
Watch the on-demand version of New Horizons in Dyslipidaemia (NHD) 2026, a virtual educational event designed for healthcare professionals involved in the management of cardiovascular risk and other lipid-related conditions.The programme is led by course directors Dr Peter Libby (Brigham and Women’s Hospital, Boston, US), Prof Kausik Ray (Imperial College London, London, UK) and Prof Erik Stroes … View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Joerg Herrmann
Research Area(s) / Expertise:

Cardio-oncology

Atherosclerosis and Hyperlipidemia

 Job title: Director, Cardio-Oncology Clinic, Mayo Clinic, Rochester, US
Joerg Herrmann, M.D., is a cardiologist researching how cancer and heart disease interact. Dr. Herrmann's research focuses on cardio-oncology, which studies the potential negative effects of cancer treatments on the circulatory system. Additionally, Dr. Herrmann is very interested in vascular illnesses, particularly the formation of atherosclerotic plaques and their effects. His work also… View more